Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Overview of attention for article published in Annals of Oncology, October 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 4 news outlets
blogs: 2 blogs
policy: 2 policy sources
twitter: 12 X users

patent: 1 patent
guideline: 8 clinical guideline sources
podcasts: 4 podcasts

Readers on

mendeley: 366 Mendeley

So far, Altmetric has seen 13 X posts from 12 X users, with an upper bound of 26,926 followers.

RT @marijasullivan: @TumorBoardTues @JenniferLitton @JasmineSukumar @Dr_RShatsky @awolff @jane_meisel @sardesai_sagar @andMORand @MassimoDi…

@TumorBoardTues @JenniferLitton @JasmineSukumar @Dr_RShatsky @awolff @jane_meisel @sardesai_sagar @andMORand @MassimoDiMaio75 @MLambouras @melindatelli @IBCradiation @TJH0828 @naborala @MuozMateu @FadwaARahman @emrekocamd @spinmaplered @LeandroJonatad1 @c…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 9 additional X posts.